Art. -Nr.: HY-15463

Imatinib

(Synonyms: STI571; CGP-57148B)

127 Cited Publications

Kundenbewertung

Based on 127 publication(s) in Google Scholar

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 152459-95-5
Formel: C₂₉H₃₁N₇O
Molecular Weight:493.60

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Imatinib Chemical Structure

CAS. Nr.: 152459-95-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (127)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively^[1]^[2]^[3]^[4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV^[5].

IC₅₀ & Target

BCR/ABL, v-Abl, PDGFR, c-kit^[1]^[2]^[4]

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen :

Abl
Bcr-Abl

Alle PDGFR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	16 μM Compound: Imatinib	Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
A10	IC₅₀	162 nM Compound: 1	Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay	[PMID: 27502700]
A2780	IC₅₀	4.8 x 10^-5 M Compound: 1	Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
A2780	IC₅₀	8.9 μM Compound: Imatinib	Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay	[PMID: 29684708]
A-431	IC₅₀	3.1 x 10^-5 M Compound: 1	Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
A498	GI₅₀	21.98 μM Compound: Imatinib	Growth inhibition of human A498 cells measured after 48 hrs by SRB assay Growth inhibition of human A498 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
A549	IC₅₀	15.5 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
A549	IC₅₀	4.56 μM Compound: Imatinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28525838]
A549	IC₅₀	>25 μM Compound: Imatinib	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
A549	GI₅₀	24.49 μM Compound: Imatinib	Growth inhibition of human A549 cells measured after 48 hrs by SRB assay Growth inhibition of human A549 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
A549	IC₅₀	65 μM Compound: Imatinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38889607]
ACHN	GI₅₀	25.23 μM Compound: Imatinib	Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay	[PMID: 32942186]
ASPC1	IC₅₀	4.4 x 10^-5 M Compound: 1	Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
B16-F10	IC₅₀	0.87 μM Compound: Imatinib	Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	15.67 μM Compound: Imatinib	Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	31.43 μM Compound: Imatinib	Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
BaF3	IC₅₀	>6400 nM Compound: STI571	Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis	[PMID: 15930265]
BaF3	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	0.027 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	0.19 μM Compound: imatinib	Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	190 nM Compound: imatinib	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	339 nM Compound: imatinib	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	393 nM Compound: imatinib	Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	55 nM Compound: imatinib	Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	88 nM Compound: imatinib	Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	962 nM Compound: imatinib	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay	[PMID: 16415863]
BaF3	IC₅₀	>100 μM Compound: Imatinib	Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay	[PMID: 16970400]
BaF3	IC₅₀	>30 μM Compound: Imatinib	Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay	[PMID: 16970400]
BaF3	IC₅₀	>30 μM Compound: Imatinib	Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay	[PMID: 16970400]
BaF3	IC₅₀	>30 μM Compound: Imatinib	Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay	[PMID: 16970400]
BaF3	IC₅₀	7.1 μM Compound: Imatinib	Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay	[PMID: 16970400]
BaF3	IC₅₀	9.1 μM Compound: Imatinib	Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay	[PMID: 16970400]
BaF3	IC₅₀	39 nM Compound: gleevec, ST1571	Antiproliferative activity against PDGFRbeta transfected mouse BA/F3 cells Antiproliferative activity against PDGFRbeta transfected mouse BA/F3 cells	[PMID: 20817538]
BaF3	IC₅₀	678 nM Compound: gleevec, ST1571	Antiproliferative activity against BCR-ABL1 transfected mouse BA/F3 cells Antiproliferative activity against BCR-ABL1 transfected mouse BA/F3 cells	[PMID: 20817538]
BaF3	IC₅₀	9459 nM Compound: gleevec, ST1571	Antiproliferative activity mouse BA/F3 cells in presence of interleukin 3 Antiproliferative activity mouse BA/F3 cells in presence of interleukin 3	[PMID: 20817538]
BaF3	IC₅₀	>10000 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	>10000 nM Compound: Imatinib	Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	10000 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	10000 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	10000 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	1700 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	190 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	1900 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2300 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2500 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	417 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	417 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	48 nM Compound: Imatinib	Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	536 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	6400 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	700 nM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	110 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	129 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1444 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	17083 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1834 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	18520 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1863 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	2377 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	2547 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	2951 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	3005 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	362 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	3763 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	424 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	8615 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	960 nM Compound: 1, STI571, Glivec	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	>10 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.24 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.5 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.59 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	1 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	1.6 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	11.1 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	12.2 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	12.2 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	12.5 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	13.5 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	3.3 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	3.6 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	5.2 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	5.6 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	9.2 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	9.5 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	>10 μM Compound: imatinib	Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay	[PMID: 23600806]
BaF3	IC₅₀	0.092 μM Compound: imatinib	Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay	[PMID: 23600806]
BaF3	IC₅₀	4.79 μM Compound: imatinib	Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay	[PMID: 23600806]
BaF3	IC₅₀	221 nM Compound: 1, Glivec, Gleevec	Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA	[PMID: 23611771]
BaF3	IC₅₀	678 nM Compound: 1, Glivec, Gleevec	Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay	[PMID: 23611771]
BaF3	IC₅₀	>1 μM Compound: Imatinib	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay	[PMID: 26195136]
BaF3	IC₅₀	14500 nM Compound: Imatinib	Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay	[PMID: 26562217]
BaF3	IC₅₀	89 nM Compound: Imatinib	Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay	[PMID: 26562217]
BaF3	GI₅₀	>10 μM Compound: Imatinib	Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	>10 μM Compound: Imatinib	Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.38 μM Compound: Imatinib	Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.5 μM Compound: Imatinib	Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.625 μM Compound: Imatinib	Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.659 μM Compound: Imatinib	Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.855 μM Compound: Imatinib	Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	1.69 μM Compound: Imatinib	Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	1.93 μM Compound: Imatinib	Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	2.1 μM Compound: Imatinib	Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	2.169 μM Compound: Imatinib	Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	3 μM Compound: Imatinib	Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	4.1 μM Compound: Imatinib	Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	6.7 μM Compound: Imatinib	Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	7.7 μM Compound: Imatinib	Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	9.7 μM Compound: Imatinib	Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	EC₅₀	34 nM Compound: Imatinib	Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 27010810]
BaF3	EC₅₀	>1000 nM Compound: Imatinib	Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 27010810]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against mouse BAF3 cells Antiproliferative activity against mouse BAF3 cells	[PMID: 27077705]
BaF3	GI₅₀	0.039 μM Compound: 1	Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.1 μM Compound: 1	Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.4 μM Compound: 1	Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	1.29 μM Compound: 1	Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	2.49 μM Compound: 1	Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	3 μM Compound: 1	Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	6.67 μM Compound: 1	Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	>10 μM Compound: 1	Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27545040]
BaF3	GI₅₀	>10 μM Compound: 1	Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.019 μM Compound: 1	Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.034 μM Compound: 1	Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.039 μM Compound: 1	Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.102 μM Compound: 1	Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.11 μM Compound: 1	Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.27 μM Compound: 1	Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.37 μM Compound: 1	Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.625 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	0.85 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	1.29 μM Compound: 1	Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	1.79 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	2.16 μM Compound: 1	Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	2.49 μM Compound: 1	Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	3 μM Compound: 1	Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	6.67 μM Compound: 1	Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
BaF3	GI₅₀	4.686 μM Compound: 1	Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
BaF3	GI₅₀	>10 μM Compound: 1	Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 29544149]
BaF3	GI₅₀	>10 μM Compound: 1	Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay	[PMID: 30204441]
BaF3	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	0.26 μM Compound: 1	Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	0.29 μM Compound: 1	Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	0.65 μM Compound: 1	Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	0.85 μM Compound: 1	Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	0.95 μM Compound: 1	Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	1.17 μM Compound: 1	Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	2.24 μM Compound: 1	Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	3.75 μM Compound: 1	Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	3.75 μM Compound: 1	Inhibition of BCR/ABL H396P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of BCR/ABL H396P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 30317026]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	>10 μM Compound: 1	Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.001 μM Compound: 1	Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.005 μM Compound: 1	Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.039 μM Compound: 1	Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.115 μM Compound: 1	Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.267 μM Compound: 1	Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.364 μM Compound: 1	Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.406 μM Compound: 1	Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	0.823 μM Compound: 1	Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	1.29 μM Compound: 1	Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	1.57 μM Compound: 1	Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	2.3 μM Compound: 1	Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31046271]
BaF3	GI₅₀	>10 μM Compound: 1	Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay	[PMID: 31250638]
BaF3	IC₅₀	>100 nM Compound: Imatinib	Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay	[PMID: 34011155]
BaF3	IC₅₀	>100 nM Compound: Imatinib	Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
BaF3	IC₅₀	0.23 μM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 35561654]
BaF3	IC₅₀	10 μM Compound: Imatinib	Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 35561654]
BJ	GI₅₀	>40 μM Compound: Imatinib	Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
BT-549	GI₅₀	16.11 μM Compound: Imatinib	Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
BV-173	IC₅₀	20 μM Compound: Imatinib	In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
BV-173	GI₅₀	0.1 μM Compound: Imatinib	Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay	[PMID: 27011159]
CAKI-1	GI₅₀	33.96 μM Compound: Imatinib	Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
CAL-27	IC₅₀	2.2 x 10^-5 M Compound: 1	Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
CCRF-CEM	IC₅₀	36 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
CCRF-CEM	IC₅₀	45 μM Compound: Imatinib	In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
CCRF-CEM	GI₅₀	35.809 μM Compound: Imatinib	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
CCRF-CEM	GI₅₀	16.98 μM Compound: Imatinib	Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay	[PMID: 32942186]
CCRF-CEM	GI₅₀	16.98 μM Compound: Imatinib	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
CCRF-CEM	GI₅₀	17.03 μM Compound: Imatinib	Anticancer activity against human CCRF-CEM cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human CCRF-CEM cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
CCRF-CEM/VCR-1000	IC₅₀	3.7 x 10^-5 M Compound: 1	Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
CHO	IC₅₀	>30 μM Compound: STI-571 imatinib	Inhibition of chimeric PDGF receptor with FLT-3 cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with FLT-3 cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	0.24 μM Compound: STI-571 imatinib	Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	0.26 μM Compound: STI-571 imatinib	Inhibition of chimeric PDGF receptor with c-kit cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with c-kit cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
CHO	IC₅₀	0.96 μM Compound: STI-571 imatinib	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	[PMID: 12166950]
CHO	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
CHO	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
CHO	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
CHO	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay	[PMID: 30317026]
COLO 205	GI₅₀	17.62 μM Compound: Imatinib	Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
DU-145	GI₅₀	18.79 μM Compound: Imatinib	Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
EKVX	GI₅₀	26.18 μM Compound: Imatinib	Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay	[PMID: 32942186]
EM-2	GI₅₀	0.26 μM Compound: Imatinib	Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay	[PMID: 27011159]
EOL1	IC₅₀	0.0002 μM Compound: 1	Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
EOL1	IC₅₀	0.2 nM Compound: 1	Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
EOL1	GI₅₀	<0.001 μM Compound: 1	Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 29544149]
EOL1	GI₅₀	<0.0005 μM Compound: Imatinib	Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
EOL1	GI₅₀	<0.5 nM Compound: Imatinib	Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
GIST430	GI₅₀	1100 nM Compound: 1	Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
GIST430	GI₅₀	929 nM Compound: Imatinib	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass	[PMID: 30968693]
GIST430	GI₅₀	929 nM Compound: Imatinib	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST430	GI₅₀	625 nM Compound: 1	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining	[PMID: 31721578]
GIST48	IC₅₀	18.7 μM Compound: imatinib	Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay	[PMID: 19469547]
GIST48	GI₅₀	625 nM Compound: Imatinib	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay	[PMID: 30968693]
GIST48	GI₅₀	625 nM Compound: Imatinib	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST48	GI₅₀	929 nM Compound: 1	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay	[PMID: 31721578]
GIST882	IC₅₀	1.7 μM Compound: imatinib	Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay	[PMID: 19469547]
GIST882	IC₅₀	108 nM Compound: gleevec, ST1571	Antiproliferative activity against human GIST882 cells Antiproliferative activity against human GIST882 cells	[PMID: 20817538]
GIST882	GI₅₀	0.014 μM Compound: 1	Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
GIST882	GI₅₀	0.014 μM Compound: 1	Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
GIST882	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
GIST882	GI₅₀	195 nM Compound: Imatinib	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay	[PMID: 30968693]
GIST882	GI₅₀	195 nM Compound: Imatinib	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST882	GI₅₀	0.058 μM Compound: 1	Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay	[PMID: 31046271]
GIST882	GI₅₀	195 nM Compound: 1	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay	[PMID: 31721578]
GISTT1	GI₅₀	0.008 μM Compound: 1	Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
GISTT1	GI₅₀	0.008 μM Compound: 1	Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
GISTT1	GI₅₀	0.003 μM Compound: 1	Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
GISTT1	GI₅₀	40 nM Compound: 1	Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
GISTT1	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay	[PMID: 31046271]
GISTT1	GI₅₀	0.026 μM Compound: 1	Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay	[PMID: 31046271]
GISTT1	GI₅₀	>10 μM Compound: 1	Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31250638]
GISTT1	GI₅₀	0.015 μM Compound: 1	Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31250638]
GISTT1	GI₅₀	40 nM Compound: 1	Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 31721578]
HCC 2998	GI₅₀	21.23 μM Compound: Imatinib	Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HCC827	GI₅₀	>40 μM Compound: Imatinib	Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
HCT-116	IC₅₀	1 x 10^-5 M Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HCT-116	IC₅₀	34.4 μM Compound: Imatinib	Anticancer activity against human HCT116 cells Anticancer activity against human HCT116 cells	[PMID: 26312434]
HCT-116	IC₅₀	19.66 μM Compound: Imatinib	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29684708]
HCT-116	IC₅₀	44.55 μM Compound: Imatinib	Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
HCT-116	IC₅₀	51.21 μM Compound: Imatinib	Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
HCT-116	GI₅₀	12.59 μM Compound: Imatinib	Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HCT-116	IC₅₀	34.3 μM Compound: Imatinib	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 33129590]
HCT-116	IC₅₀	34.3 μM Compound: Imatinib	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 33129590]
HCT-15	IC₅₀	2.5 x 10^-5 M Compound: 1	Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HCT-15	GI₅₀	19.95 μM Compound: Imatinib	Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HEC-1-A	IC₅₀	1.9 x 10^-5 M Compound: 1	Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HEK293	IC₅₀	>100 μM Compound: 1	Inhibition of human recombinant HDAC1 expressed in HEK293 cells Inhibition of human recombinant HDAC1 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	>100 μM Compound: 1	Inhibition of human recombinant HDAC6 expressed in HEK293 cells Inhibition of human recombinant HDAC6 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	141 nM Compound: gleevec, ST1571	Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA	[PMID: 20817538]
HEK293	IC₅₀	291 nM Compound: gleevec, ST1571	Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA	[PMID: 20817538]
HEK293	IC₅₀	43 nM Compound: gleevec, ST1571	Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA	[PMID: 20817538]
HEK293	IC₅₀	0.05 μM Compound: imatinib	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	[PMID: 23241029]
HEK293	IC₅₀	0.35 μM Compound: imatinib	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	0.35 μM Compound: imatinib	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	107 μM Compound: imatinib	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	2.9 μM Compound: imatinib	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	25.5 μM Compound: imatinib	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	4.2 μM Compound: imatinib	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	CC₅₀	8.4 μM Compound: Imatinib	Cytotoxicity against HEK293 cells assessed as reduction in cell viability Cytotoxicity against HEK293 cells assessed as reduction in cell viability	[PMID: 26264503]
HEK293	IC₅₀	>10 μM Compound: STI571	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay	[PMID: 35944901]
HEK-293T	CC₅₀	20.53 μM Compound: Imatinib	Cytotoxicity against human 293T cells assessed as growth inhibition Cytotoxicity against human 293T cells assessed as growth inhibition	[PMID: 26850004]
HEK-293T	CC₅₀	27.54 μM Compound: Imatinib	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 28029512]
HEL	GI₅₀	5.3 μM Compound: Imatinib	Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
HeLa	EC₅₀	>100 μM Compound: 1	Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation	[PMID: 19301902]
HeLa	IC₅₀	18.65 μM Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HeLa	CC₅₀	38.8 μg/mL Compound: imatinib	Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining	[PMID: 20153202]
HeLa	CC₅₀	65.8 μM Compound: Imatinib	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 22439674]
HeLa	CC₅₀	>10 μg/mL Compound: Imatinib	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 25372601]
HepG2	IC₅₀	10 μM Compound: Imatinib	Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay	[PMID: 23932071]
HepG2	IC₅₀	>25 μM Compound: Imatinib	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26707846]
HepG2	IC₅₀	0.91 μM Compound: Imatinib	Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	27.74 μM Compound: Imatinib	Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	74.52 μM Compound: Imatinib	Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
HGC-27	IC₅₀	2.4 μM Compound: imatinib	Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay	[PMID: 19469547]
HGC-27	IC₅₀	3.8 μM Compound: Imatinib	Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24900584]
HGC-27	IC₅₀	2.4 μM Compound: Imatinib	Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay	[PMID: 29724653]
HL-60	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 16415863]
HL-60	IC₅₀	55 μM Compound: Imatinib	In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
HL-60	IC₅₀	0.03 μM Compound: Imatinib	Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay	[PMID: 26850004]
HL-60	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
HL-60	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
HL-60	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
HL-60	IC₅₀	28.54 μM Compound: Imatinib	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
HL-60	IC₅₀	17.2 μM Compound: Imatinib	Antitumor activity against human HL-60 cells assessed as inhibition of cell growth Antitumor activity against human HL-60 cells assessed as inhibition of cell growth	[PMID: 36681201]
HL-60	GI₅₀	13.54 μM Compound: Imatinib	Anticancer activity against human HL-60 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human HL-60 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
HL-60(TB)	GI₅₀	13.49 μM Compound: Imatinib	Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HL-60(TB)	GI₅₀	13.49 μM Compound: Imatinib	Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
HOP-62	GI₅₀	21.53 μM Compound: Imatinib	Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HOP-92	GI₅₀	13.34 μM Compound: Imatinib	Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HOS-TE85	IC₅₀	20.5 μM Compound: Imatinib	Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35239349]
Hs-578T	GI₅₀	14.59 μM Compound: Imatinib	Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HT-29	IC₅₀	0.06 μM Compound: imatinib	Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 19469547]
HT-29	IC₅₀	0.06 μM Compound: Imatinib	Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29724653]
HT-29	GI₅₀	3.97 μM Compound: Imatinib	Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
HUVEC	GI₅₀	10.9 μg/mL Compound: imatinib	Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay	[PMID: 20153202]
HUVEC	GI₅₀	18.5 μM Compound: Imatinib	Antiproliferative activity against HUVEC cells Antiproliferative activity against HUVEC cells	[PMID: 22439674]
HUVEC	GI₅₀	>10 μg/mL Compound: Imatinib	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 25372601]
IGROV-1	GI₅₀	21.18 μM Compound: Imatinib	Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
Jurkat	IC₅₀	>10 μM Compound: imatinib	Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
Jurkat	IC₅₀	>1000 nM Compound: Imatinib	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
K562	IC₅₀	0.11 μM Compound: STI-571 imatinib	Cytotoxic effect in K562 cells Cytotoxic effect in K562 cells	[PMID: 12951113]
K562	IC₅₀	0.4 μM Compound: STI-571 imatinib	Inhibitory activity against human K562 cells growth using MTT assay Inhibitory activity against human K562 cells growth using MTT assay	[PMID: 14552760]
K562	IC₅₀	182 nM Compound: STI-571	Antiproliferative activity against K562 cells Antiproliferative activity against K562 cells	[PMID: 16332440]
K562	IC₅₀	0.109 μM Compound: imatinib	Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
K562	IC₅₀	0.18 μM Compound: gleevec	Cytotoxicity against K562 cells by MTT assay Cytotoxicity against K562 cells by MTT assay	[PMID: 17572088]
K562	IC₅₀	0.049 μM Compound: 1	Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
K562	GI₅₀	0.1 ng/mL Compound: imatinib	Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay	[PMID: 20153202]
K562	GI₅₀	0.1 x 10^-3 μg/mL Compound: imatinib	Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay	[PMID: 20153202]
K562	IC₅₀	0.75 μM Compound: Imatinib	Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis	[PMID: 20188579]
K562	IC₅₀	244 nM Compound: gleevec, ST1571	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 20817538]
K562	IC₅₀	473 nM Compound: gleevec, ST1571	Inhibition of BCR-ABL1 autophosphorylation in human K562 cells Inhibition of BCR-ABL1 autophosphorylation in human K562 cells	[PMID: 20817538]
K562	IC₅₀	0.58 μM Compound: Imatinib	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21295380]
K562	IC₅₀	380 nM Compound: Imatinib	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 21376587]
K562	IC₅₀	6.05 nM Compound: Imatinib	Antiproliferative activity against human imatinib-resistant K562 cells Antiproliferative activity against human imatinib-resistant K562 cells	[PMID: 21376587]
K562	IC₅₀	5.4 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 21576023]
K562	GI₅₀	0.17 μM Compound: Imatinib	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 22439674]
K562	IC₅₀	0.1 μM Compound: Imatinib	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 22632935]
K562	IC₅₀	384.4 nM Compound: STI571, Gleevec	Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay	[PMID: 22789429]
K562	GI₅₀	0.39 μM Compound: 1, Gleevec	Cytotoxicity against human K562 cells after 72 hrs by MTS assay Cytotoxicity against human K562 cells after 72 hrs by MTS assay	[PMID: 22932313]
K562	IC₅₀	0.5 μM Compound: Imatinib	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 23352483]
K562	IC₅₀	0.17 μM Compound: imatinib	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 23600806]
K562	IC₅₀	0.47 μM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23735826]
K562	IC₅₀	0.5 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 23932071]
K562	IC₅₀	0.5 μM Compound: Imatinib	Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay	[PMID: 23981532]
K562	IC₅₀	13 μM Compound: Imatinib	In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
K562	GI₅₀	0.1 μg/mL Compound: Imatinib	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 25372601]
K562	IC₅₀	4.12 μM Compound: Imatinib	Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method	[PMID: 25464886]
K562	IC₅₀	0.5 μM Compound: imatinib	Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay	[PMID: 25757603]
K562	IC₅₀	0.47 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25778766]
K562	IC₅₀	0.28 μM Compound: Imatinib	Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay	[PMID: 26195136]
K562	IC₅₀	1.16 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26231079]
K562	IC₅₀	15.7 μM Compound: Imatinib	Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay	[PMID: 26231079]
K562	IC₅₀	0.06 μM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as reduction in cell viability Cytotoxicity against human K562 cells assessed as reduction in cell viability	[PMID: 26264503]
K562	IC₅₀	4.12 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26298495]
K562	IC₅₀	1.16 μM Compound: STI571	Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26451772]
K562	IC₅₀	0.22 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay	[PMID: 26629859]
K562	IC₅₀	0.53 μM Compound: Imatinib	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 26707846]
K562	IC₅₀	0.73 μM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method	[PMID: 26741853]
K562	GI₅₀	0.14 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
K562	IC₅₀	0.51 μM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26814890]
K562	IC₅₀	0.38 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay	[PMID: 26850004]
K562	GI₅₀	0.2 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay	[PMID: 27011159]
K562	GI₅₀	0.12 μM Compound: 1	Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
K562	IC₅₀	0.5 μM Compound: Imatinib	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 27189674]
K562	IC₅₀	310 nM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay	[PMID: 27214512]
K562	GI₅₀	0.267 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
K562	IC₅₀	7.38 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 28029512]
K562	IC₅₀	250 nM Compound: Imatinib	Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method	[PMID: 28280261]
K562	IC₅₀	272 nM Compound: Imatinib	Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method	[PMID: 28280261]
K562	IC₅₀	43 nM Compound: Imatinib	Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method	[PMID: 28280261]
K562	IC₅₀	90 nM Compound: Imatinib	Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method	[PMID: 28280261]
K562	IC₅₀	0.53 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28525838]
K562	GI₅₀	0.147 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
K562	IC₅₀	1.1 μM Compound: Imatinib	Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay	[PMID: 29655981]
K562	IC₅₀	3.43 μM Compound: Imatinib	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29684708]
K562	IC₅₀	1 μM Compound: IM	Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay	[PMID: 30261468]
K562	GI₅₀	0.25 μM Compound: 1	Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
K562	IC₅₀	0.15 nM Compound: Imatinib	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 30605831]
K562	IC₅₀	0.14 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique	[PMID: 31097376]
K562	IC₅₀	4.26 μM Compound: STI-571	Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 31185413]
K562	GI₅₀	0.73 μM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
K562	IC₅₀	76.2 nM Compound: Imatinib	Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay	[PMID: 32657579]
K562	GI₅₀	0.02 μM Compound: Imatinib	Growth inhibition of human K562 cells measured after 48 hrs by SRB assay Growth inhibition of human K562 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
K562	GI₅₀	0.02 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
K562	GI₅₀	0.8 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32961435]
K562	IC₅₀	0.61 μM Compound: Imatinib	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 33132117]
K562	IC₅₀	87.32 μM Compound: Imatinib	Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 33938746]
K562	IC₅₀	82.9 nM Compound: Imatinib	Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34011155]
K562	IC₅₀	4.63 μM Compound: Imatinib	Antiproliferative activity against human K562 cells by MTS assay Antiproliferative activity against human K562 cells by MTS assay	[PMID: 34015503]
K562	IC₅₀	4.26 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 34547714]
K562	IC₅₀	1.1 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35561654]
K562	GI₅₀	>10 μM Compound: STI571	Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay	[PMID: 35944901]
K562	GI₅₀	0.563 μM Compound: STI571	Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay	[PMID: 35944901]
K562	IC₅₀	0.135 μM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
K562	IC₅₀	13.97 μM Compound: Imatinib	Antitumor activity against human K562 cells assessed as inhibition of cell growth Antitumor activity against human K562 cells assessed as inhibition of cell growth	[PMID: 36681201]
K562	GI₅₀	0.05 μM Compound: Imatinib	Anticancer activity against human K562 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human K562 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
K562	IC₅₀	179.3 nM Compound: Imatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
K562/A02	IC₅₀	0.98 μM Compound: Imatinib	Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay	[PMID: 33132117]
K562/A02	IC₅₀	75.69 μM Compound: Imatinib	Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay	[PMID: 33938746]
K562/Adr	IC₅₀	13.47 μM Compound: Imatinib	Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35561654]
K-562R	IC₅₀	>50 μM Compound: Imatinib	Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay	[PMID: 29655981]
K-562R	IC₅₀	98.82 μM Compound: IM	Cytotoxicity against human K562R cells assessed as decrease in cell viability after 24 hrs by XTT assay Cytotoxicity against human K562R cells assessed as decrease in cell viability after 24 hrs by XTT assay	[PMID: 30261468]
K-562R	IC₅₀	90 μM Compound: STI-571	Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 31185413]
K-562R	IC₅₀	93.01 μM Compound: Imatinib	Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35561654]
KBM5	IC₅₀	0.28 μM Compound: STI-571	Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTT assay Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTT assay	[PMID: 20149665]
KBM5	IC₅₀	5.4 μM Compound: STI-571	Cytotoxicity against human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTT assay Cytotoxicity against human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTT assay	[PMID: 20149665]
KCL-22	GI₅₀	0.43 μM Compound: Imatinib	Antiproliferative activity against human KCL22 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay Antiproliferative activity against human KCL22 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay	[PMID: 27011159]
KG-1a	IC₅₀	16.7 μM Compound: Imatinib	Antiproliferative activity against human KG1a cells assessed as inhibition of cell survival after 72 hrs by MTT assay Antiproliferative activity against human KG1a cells assessed as inhibition of cell survival after 72 hrs by MTT assay	[PMID: 26850004]
KM12	GI₅₀	18.84 μM Compound: Imatinib	Growth inhibition of human KM12 cells measured after 48 hrs by SRB assay Growth inhibition of human KM12 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
KU812 cell line	IC₅₀	337 nM Compound: Imatinib	Antiproliferative activity against human KU812 cells Antiproliferative activity against human KU812 cells	[PMID: 21376587]
KU812 cell line	GI₅₀	0.16 μM Compound: Imatinib	Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
KU812 cell line	GI₅₀	0.16 μM Compound: 1	Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
KU812 cell line	GI₅₀	0.163 μM Compound: 1	Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
KU812 cell line	GI₅₀	0.11 μM Compound: 1	Antiproliferative activity against human KU812 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against human KU812 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
KU812 cell line	GI₅₀	0.31 μM Compound: 1	Antiproliferative activity in human KU812 cells after 72 hrs by CCK8 assay Antiproliferative activity in human KU812 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
KU812 cell line	IC₅₀	51.3 nM Compound: Imatinib	Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
L02	IC₅₀	>100 μM Compound: Imatinib	Antiproliferative activity against human L02 cells by MTS assay Antiproliferative activity against human L02 cells by MTS assay	[PMID: 34015503]
L132	GI₅₀	>10 μM Compound: Imatinib	Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32961435]
Leukemia cell	IC₅₀	350 nM Compound: imatinib	Antiproliferative activity against human CML cells Antiproliferative activity against human CML cells	[PMID: 19219016]
Leukemia cell	IC₅₀	0.1 μM Compound: 4	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
Leukemia cell	IC₅₀	0.5 μM Compound: 4	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
LOX IMVI	GI₅₀	18.11 μM Compound: Imatinib	Growth inhibition of human LOX IMVI cells measured after 48 hrs by SRB assay Growth inhibition of human LOX IMVI cells measured after 48 hrs by SRB assay	[PMID: 32942186]
M14	GI₅₀	19.28 μM Compound: Imatinib	Growth inhibition of human M14 cells measured after 48 hrs by SRB assay Growth inhibition of human M14 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
Malme-3M	GI₅₀	16.33 μM Compound: Imatinib	Growth inhibition of human Malme-3M cells measured after 48 hrs by SRB assay Growth inhibition of human Malme-3M cells measured after 48 hrs by SRB assay	[PMID: 32942186]
MCF-10A	IC₅₀	>100 μM Compound: Imatinib	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30798049]
MCF7	IC₅₀	3 x 10^-5 M Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human MCF7 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
MCF7	IC₅₀	11.5 μM Compound: imatinib	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 19469547]
MCF7	IC₅₀	4.07 μM Compound: Imatinib	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MCF7	IC₅₀	>10 μM Compound: Imatinib	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 23352483]
MCF7	IC₅₀	>10 μM Compound: Imatinib	Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay	[PMID: 23981532]
MCF7	IC₅₀	>10 μM Compound: imatinib	Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay	[PMID: 25757603]
MCF7	IC₅₀	>10 μM Compound: Imatinib	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method	[PMID: 26741853]
MCF7	IC₅₀	>10 μM Compound: Imatinib	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 27189674]
MCF7	IC₅₀	7.12 μM Compound: Imatinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29684708]
MCF7	IC₅₀	11.3 μM Compound: Imatinib	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29724653]
MCF7	IC₅₀	>25 μM Compound: Imatinib	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
MCF7	IC₅₀	6.33 μM Compound: Imatinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30798049]
MCF7	GI₅₀	18.24 μM Compound: Imatinib	Growth inhibition of human MCF7 cells measured after 48 hrs by SRB assay Growth inhibition of human MCF7 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
MCF7	IC₅₀	25.55 μM Compound: Imatinib	Antitumor activity against human MCF7 cells assessed as inhibition of cell growth Antitumor activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 36681201]
MDA-MB-231	IC₅₀	3.7 x 10^-5 M Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
MDA-MB-231	GI₅₀	18.66 μM Compound: Imatinib	Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
MDA-MB-435	GI₅₀	17.91 μM Compound: Imatinib	Growth inhibition of human MDA-MB-435 cells measured after 48 hrs by SRB assay Growth inhibition of human MDA-MB-435 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
MDA-MB-453	IC₅₀	12.84 μM Compound: Imatinib	Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30798049]
MDA-MB-468	IC₅₀	1.7 x 10^-5 M Compound: 1	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human MDA-MB-468 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
MDCK	IC₅₀	3.38 μM Compound: Imatinib	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
MDCK-II	IC₅₀	0.04 μM Compound: imatinib	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	[PMID: 23241029]
MDCK-II	IC₅₀	>100 μM Compound: Imatinib	Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay	[PMID: 33938746]
MDCK-II	IC₅₀	65.82 μM Compound: Imatinib	Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay	[PMID: 33938746]
MEC1	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in human MEC1 cells after 72 hrs by CCK8 assay Antiproliferative activity in human MEC1 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
MEG-01	GI₅₀	0.24 μM Compound: Imatinib	Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
MEG-01	GI₅₀	0.074 μM Compound: 1	Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MEG-01	GI₅₀	0.074 μM Compound: 1	Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
MEG-01	GI₅₀	0.045 μM Compound: 1	Antiproliferative activity against human MEG01 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Antiproliferative activity against human MEG01 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 28541695]
MEG-01	GI₅₀	0.28 μM Compound: 1	Antiproliferative activity in human MEG01 cells after 72 hrs by CCK8 assay Antiproliferative activity in human MEG01 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
MG-63	IC₅₀	31.69 μM Compound: Imatinib	Antiproliferative activity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35239349]
MOLM-13	GI₅₀	>1000 nM Compound: 1	Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 31721578]
MOLM-14	GI₅₀	>10 μM Compound: Imatinib	Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
MOLM-14	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MOLM-14	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
MOLT-4	GI₅₀	5.13 μM Compound: Imatinib	Growth inhibition of human MOLT-4 cells measured after 48 hrs by SRB assay Growth inhibition of human MOLT-4 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
MOLT-4	GI₅₀	5.13 μM Compound: Imatinib	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
MOLT-4	GI₅₀	5.13 μM Compound: Imatinib	Anticancer activity against human MOLT-4 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human MOLT-4 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
MV4-11	GI₅₀	>10 μM Compound: Imatinib	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
MV4-11	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MV4-11	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
NCI/ADR-RES	GI₅₀	22.96 μM Compound: Imatinib	Growth inhibition of human NCI/ADR-RES cells measured after 48 hrs by SRB assay Growth inhibition of human NCI/ADR-RES cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H1703	GI₅₀	0.23 μM Compound: 1	Antiproliferative activity against human NCI-H1703 cells after 72 hrs in presence of PDGF-AA by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human NCI-H1703 cells after 72 hrs in presence of PDGF-AA by CellTiter-Glo or CCK-8 assay	[PMID: 29544149]
NCI-H1703	GI₅₀	2.1 μM Compound: 1	Antiproliferative activity against human NCI-H1703 cells after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human NCI-H1703 cells after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 29544149]
NCI-H226	GI₅₀	18.11 μM Compound: Imatinib	Growth inhibition of human NCI-H226 cells measured after 48 hrs by SRB assay Growth inhibition of human NCI-H226 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H23	GI₅₀	14.96 μM Compound: Imatinib	Growth inhibition of human NCI-H23 cells measured after 48 hrs by SRB assay Growth inhibition of human NCI-H23 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H322M	GI₅₀	22.8 μM Compound: Imatinib	Growth inhibition of human NCI-H322M cells measured after 48 hrs by SRB assay Growth inhibition of human NCI-H322M cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H460	IC₅₀	2.4 x 10^-5 M Compound: 1	Cytotoxicity against human H460 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human H460 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
NCI-H460	GI₅₀	16.18 μM Compound: Imatinib	Growth inhibition of human NCI-H460 cells measured after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H522	GI₅₀	16.41 μM Compound: Imatinib	Growth inhibition of human NCI-H522 cells measured after 48 hrs by SRB assay Growth inhibition of human NCI-H522 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
NCI-H69	IC₅₀	3.2 x 10^-5 M Compound: 1	Cytotoxicity against human H69 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human H69 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
NFS-60	IC₅₀	358 nM Compound: gleevec, ST1571	Antiproliferative activity against mouse M-NFS-60 cells Antiproliferative activity against mouse M-NFS-60 cells	[PMID: 20817538]
NHDF	IC₅₀	>25 μM Compound: Imatinib	Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
OCI-AML2	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in human OCI-AML2 cells after 72 hrs by CCK8 assay Antiproliferative activity in human OCI-AML2 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
OVCAR-3	GI₅₀	34.2 μM Compound: Imatinib	Growth inhibition of human OVCAR-3 cells measured after 48 hrs by SRB assay Growth inhibition of human OVCAR-3 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
OVCAR-4	GI₅₀	20.04 μM Compound: Imatinib	Growth inhibition of human OVCAR-4 cells measured after 48 hrs by SRB assay Growth inhibition of human OVCAR-4 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
OVCAR-5	GI₅₀	0.58 μM Compound: Imatinib	Growth inhibition of human OVCAR-5 cells measured after 48 hrs by SRB assay Growth inhibition of human OVCAR-5 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
OVCAR-8	GI₅₀	27.67 μM Compound: Imatinib	Growth inhibition of human OVCAR-8 cells measured after 48 hrs by SRB assay Growth inhibition of human OVCAR-8 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
PBMC	IC₅₀	159 μM Compound: Imatinib	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay	[PMID: 38064359]
PC-3	IC₅₀	2.4 x 10^-5 M Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human PC3 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
PC-3	GI₅₀	21.38 μM Compound: Imatinib	Growth inhibition of human PC-3 cells measured after 48 hrs by SRB assay Growth inhibition of human PC-3 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
Rec1	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
Rec1	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
RPMI-8226	GI₅₀	6.05 μM Compound: Imatinib	Growth inhibition of human RPMI-8226 cells measured after 48 hrs by SRB assay Growth inhibition of human RPMI-8226 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
RPMI-8226	GI₅₀	6.05 μM Compound: Imatinib	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
RPMI-8226	GI₅₀	6.17 μM Compound: Imatinib	Anticancer activity against human RPMI-8226 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human RPMI-8226 cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
RXF 393	GI₅₀	15.07 μM Compound: Imatinib	Growth inhibition of human RXF 393 cells measured after 48 hrs by SRB assay Growth inhibition of human RXF 393 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SAOS-2	IC₅₀	2.6 x 10^-5 M Compound: 1	Cytotoxicity against human Saos2 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human Saos2 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
SAOS-2	IC₅₀	15.01 μM Compound: Imatinib	Antiproliferative activity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35239349]
SCH	IC₅₀	4.7 μM Compound: 1; , STI-571	Antiproliferative activity against human SCH cells assessed as reduction in cell viability Antiproliferative activity against human SCH cells assessed as reduction in cell viability	[PMID: 31923860]
SF-268	GI₅₀	26.3 μM Compound: Imatinib	Growth inhibition of human SF-268 cells measured after 48 hrs by SRB assay Growth inhibition of human SF-268 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SF-295	GI₅₀	19.77 μM Compound: Imatinib	Growth inhibition of human SF-295 cells measured after 48 hrs by SRB assay Growth inhibition of human SF-295 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SF-539	GI₅₀	10.57 μM Compound: Imatinib	Growth inhibition of human SF-539 cells measured after 48 hrs by SRB assay Growth inhibition of human SF-539 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
Sf9	IC₅₀	0.5 μM Compound: Imatinib (STI-571)	TP_TRANSPORTER: inhibition of ATPase activity in BCRP-expressing Sf9 cells TP_TRANSPORTER: inhibition of ATPase activity in BCRP-expressing Sf9 cells	[PMID: 15155841]
Sf9	IC₅₀	0.9 μM Compound: Imatinib (STI-571)	TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells	[PMID: 15155841]
Sf9	IC₅₀	220 nM Compound: 1, imatinib, STI-571	Inhibition of human Lyn kinase expressed in Sf9 cells Inhibition of human Lyn kinase expressed in Sf9 cells	[PMID: 17376680]
Sf9	IC₅₀	470 nM Compound: 1, imatinib, STI-571	Inhibition of human Abl kinase expressed in Sf9 cells Inhibition of human Abl kinase expressed in Sf9 cells	[PMID: 17376680]
Sf9	IC₅₀	>100 μM Compound: Imatinib	Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP	[PMID: 24681986]
Sf9	IC₅₀	0.3 μM Compound: Imatinib	Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP	[PMID: 24681986]
Sf9	IC₅₀	>100 μM Compound: Imatinib	Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP	[PMID: 26741853]
Sf9	IC₅₀	319 nM Compound: 1	Inhibition of His-tagged cKIT (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay Inhibition of His-tagged cKIT (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay	[PMID: 27545040]
Sf9	IC₅₀	9818 nM Compound: 1	Inhibition of His-tagged cKIT T670I mutant (544 to 935 residues) (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay Inhibition of His-tagged cKIT T670I mutant (544 to 935 residues) (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay	[PMID: 27545040]
Sf9	IC₅₀	223 nM Compound: 1	Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay	[PMID: 27966954]
Sf9	IC₅₀	>10 μM Compound: 1	Inhibition of active wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay Inhibition of active wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay	[PMID: 30317026]
Sf9	IC₅₀	>10 μM Compound: 1	Inhibition of inactive wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8 Inhibition of inactive wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8	[PMID: 30317026]
Sf9	IC₅₀	0.043 μM Compound: 1	Inhibition of inactive wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8 hrs by ADP-G Inhibition of inactive wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8 hrs by ADP-G	[PMID: 30317026]
Sf9	IC₅₀	1.5 μM Compound: 1	Inhibition of active wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay Inhibition of active wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay	[PMID: 30317026]
Sf9	IC₅₀	5210 nM Compound: Imatinib	Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3 Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3	[PMID: 30968693]
Sf9	IC₅₀	769 nM Compound: Imatinib	Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30 Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30	[PMID: 30968693]
Sf9	IC₅₀	131 nM Compound: 1	Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine	[PMID: 31721578]
Sf9	IC₅₀	53 nM Compound: 1	Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of	[PMID: 31721578]
SK-BR-3	IC₅₀	3.9 x 10^-5 M Compound: 1	Cytotoxicity against human SKBR3 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human SKBR3 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
SK-MEL-2	GI₅₀	25 μM Compound: Imatinib	Growth inhibition of human SK-MEL-2 cells measured after 48 hrs by SRB assay Growth inhibition of human SK-MEL-2 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SK-MEL-28	GI₅₀	14.62 μM Compound: Imatinib	Growth inhibition of human SK-MEL-28 cells measured after 48 hrs by SRB assay Growth inhibition of human SK-MEL-28 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SK-MEL-5	GI₅₀	12.13 μM Compound: Imatinib	Growth inhibition of human SK-MEL-5 cells measured after 48 hrs by SRB assay Growth inhibition of human SK-MEL-5 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SK-OV-3	IC₅₀	5.3 x 10^-5 M Compound: 1	Cytotoxicity against human SKOV3 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human SKOV3 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
SK-OV-3	GI₅₀	28.91 μM Compound: Imatinib	Growth inhibition of human SK-OV-3 cells measured after 48 hrs by SRB assay Growth inhibition of human SK-OV-3 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SN12C	GI₅₀	33.19 μM Compound: Imatinib	Growth inhibition of human SN12C cells measured after 48 hrs by SRB assay Growth inhibition of human SN12C cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SNB-19	GI₅₀	38.55 μM Compound: Imatinib	Growth inhibition of human SNB-19 cells measured after 48 hrs by SRB assay Growth inhibition of human SNB-19 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SNB-75	GI₅₀	20.28 μM Compound: Imatinib	Growth inhibition of human SNB-75 cells measured after 48 hrs by SRB assay Growth inhibition of human SNB-75 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SR	GI₅₀	7.14 μM Compound: Imatinib	Growth inhibition of human SR cells measured after 48 hrs by SRB assay Growth inhibition of human SR cells measured after 48 hrs by SRB assay	[PMID: 32942186]
SR	GI₅₀	7.14 μM Compound: Imatinib	Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32961435]
SR	GI₅₀	7.24 μM Compound: Imatinib	Anticancer activity against human SR cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control Anticancer activity against human SR cells assessed as growth inhibition measured after 48 hrs by SRB assay relative to control	[PMID: 37354740]
SUP-B15	IC₅₀	0.111 μM Compound: imatinib	Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay	[PMID: 16415863]
SW-620	GI₅₀	23.44 μM Compound: Imatinib	Growth inhibition of human SW-620 cells measured after 48 hrs by SRB assay Growth inhibition of human SW-620 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
T47D	GI₅₀	19.91 μM Compound: Imatinib	Growth inhibition of human T47D cells measured after 48 hrs by SRB assay Growth inhibition of human T47D cells measured after 48 hrs by SRB assay	[PMID: 32942186]
TF-1	IC₅₀	>5 μM Compound: 4	Cytotoxicity against human TF1 cells expressing FLT3 mutation assessed as cell viability Cytotoxicity against human TF1 cells expressing FLT3 mutation assessed as cell viability	[PMID: 22221201]
TF-1	IC₅₀	0.013 μM Compound: 4	Cytotoxicity against human TF1 cells expressing c-KIT mutation assessed as cell viability Cytotoxicity against human TF1 cells expressing c-KIT mutation assessed as cell viability	[PMID: 22221201]
THP-1	IC₅₀	25 μM Compound: Imatinib	Cytotoxicity against human THP1 cells assessed as reduction in cell viability Cytotoxicity against human THP1 cells assessed as reduction in cell viability	[PMID: 26264503]
TK-10	GI₅₀	26.85 μM Compound: Imatinib	Growth inhibition of human TK-10 cells measured after 48 hrs by SRB assay Growth inhibition of human TK-10 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
U-251	GI₅₀	17.99 μM Compound: Imatinib	Growth inhibition of human U-251 cells measured after 48 hrs by SRB assay Growth inhibition of human U-251 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
U2OS	IC₅₀	27.15 μM Compound: Imatinib	Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35239349]
U-87MG ATCC	IC₅₀	3.8 x 10^-5 M Compound: 1	Cytotoxicity against human U87MG cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human U87MG cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
U-937	IC₅₀	14 μM Compound: STI-571	Antiproliferative activity against U937 cells Antiproliferative activity against U937 cells	[PMID: 16332440]
U-937	IC₅₀	19 μM Compound: Imatinib	Cytotoxicity against human U937 cells assessed as reduction in cell viability Cytotoxicity against human U937 cells assessed as reduction in cell viability	[PMID: 26264503]
U-937	GI₅₀	>10 μM Compound: Imatinib	Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
U-937	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
U-937	GI₅₀	>10 μM Compound: 1	Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay	[PMID: 27966954]
U-937	IC₅₀	12.44 μM Compound: Imatinib	Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 28029512]
U-937	GI₅₀	>10 μM Compound: 1	Antiproliferative activity in human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity in human U937 cells after 72 hrs by CCK8 assay	[PMID: 30317026]
U-937	IC₅₀	>1000 nM Compound: Imatinib	Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
U-937	IC₅₀	16.59 μM Compound: Imatinib	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
UACC-257	GI₅₀	21.13 μM Compound: Imatinib	Growth inhibition of human UACC-257 cells measured after 48 hrs by SRB assay Growth inhibition of human UACC-257 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
UACC-62	GI₅₀	19.01 μM Compound: Imatinib	Growth inhibition of human UACC-62 cells measured after 48 hrs by SRB assay Growth inhibition of human UACC-62 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
UO-31	GI₅₀	22.34 μM Compound: Imatinib	Growth inhibition of human UO-31 cells measured after 48 hrs by SRB assay Growth inhibition of human UO-31 cells measured after 48 hrs by SRB assay	[PMID: 32942186]
WM 266-4	IC₅₀	3.7 x 10^-5 M Compound: 1	Cytotoxicity against human WM266.4 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human WM266.4 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]

In Vitro

Imatinib (STI571) inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM^[1].
Imatinib (STI571) is very effective (in vitro IC₅₀ of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC₅₀, 410 nM) and PDGFR (in vitro IC₅₀, 380 nM)^[2].
Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC₅₀ of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2^[4].
The IC₅₀s of Imatinib(STI571) is a multi-target inhibitor of v-Abl, c-Kit and on BON-1 and H727 cells after exposure for 48 h are 32.4 and 32.8 μM, respectively^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, tumor growth is inhibited by 59.437%, which is markedly higher than in the Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and group (11.071%) and liposome negative control group (2.759%). Telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158) compare with the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163)^[7].
Imatinib (25 mg/kg/day, p.o.) suppresses the growth of endometriotic tissue and reduces the number of ovarian follicles in a rat model. Imatinib effectively treats experimental endometriosis by its inhibitor effects on angiogenesis and cell proliferation^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 152459-95-5
Appearance Solid
Molecular Weight 493.60
Formel C₂₉H₃₁N₇O
Color White to light yellow
SMILES

CN(CC1)CCN1CC2=CC=C(C(NC3=CC=C(C)C(NC4=NC(C5=CC=CN=C5)=CC=N4)=C3)=O)C=C2
Synonyms

STI571; CGP-57148B
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (127)

All WBCell Proliferation/Viability AssayIHC

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN. [Abstract]

2023 Mar 1;8(1):90. PMID: 36854750
Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Nat Immunol

Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. [Abstract]

2023 Sep;24(9):1443-1457. PMID: 37563309
Nat Biomed Eng

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. [Abstract]

2018 Aug;2(8):578-588. PMID: 31015631
Cancer Commun (Lond)

Unfolded protein response kinase PERK supports survival and metastasis of circulating tumor cell clusters via SAM synthesis and H3K4me3-dependent PDGFB signaling. [Abstract]

2025 Nov 10. PMID: 41212905
Cancer Res

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [Abstract]

2025 Jan 2;85(1):101-117. PMID: 39437162
Sci Immunol

Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. [Abstract]

2023 Mar 17;8(81):eade4656. PMID: 36897957
Nat Commun

PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. [Abstract]

2025 Jul 24;16(1):6777. PMID: 40707483
Nat Commun

Evaluation of Cas13d as a tool for genetic interaction mapping. [Abstract]

2025 Feb 14;16(1):1631. PMID: 39952934
Bone Res

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization. [Abstract]

2024 Apr 10;12(1):24. PMID: 38594260
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Adv Sci (Weinh)

Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy. [Abstract]

2024 Jul 2:e2402107. PMID: 38953306
Exp Hematol Oncol

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia. [Abstract]

2024 Dec 18;13(1):121. PMID: 39696470
Theranostics

KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. [Abstract]

2021 Jan 1;11(6):2691-2705. PMID: 33456567
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Mol Ther

Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. [Abstract]

2023 Feb 1;31(2):503-516. PMID: 36384875
Cell Rep Med

FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [Abstract]

2026 Mar 17;7(3):102686. PMID: 41850237
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Clin Cancer Res

Predicting c-KIT Inhibitor Efficacy in Patient-Derived Models of Sinonasal Mucosal Melanomas through Integrated Histogram Analysis of Whole-Tumor DKI, IVIM, and DCE-MRI. [Abstract]

2025 May 1;31(9):1686-1699. PMID: 39937224
Clin Cancer Res

AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. [Abstract]

2020 Aug 15;26(16):4349-4359. PMID: 32439698
Cancer Lett

TRIM21 drives glioblastoma malignancy via ubiquitination-mediated PDGFRA degradation. [Abstract]

2026 Aug 10:653:218551. PMID: 42066836
Cancer Lett

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. [Abstract]

2019 Apr 10:447:105-114. PMID: 30684595
Cell Death Dis

RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1. [Abstract]

2026 Apr 24;17(1):548. PMID: 42031733
Cell Death Dis

Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells. [Abstract]

2022 Apr 20;13(4):384. PMID: 35444236
Acta Pharmacol Sin

Circulating small extracellular vesicles promote proliferation and migration of vascular smooth muscle cells via AXL and MerTK activation. [Abstract]

2023 May;44(5):984-998. PMID: 36450791
EMBO J

Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers. [Abstract]

2025 Nov 3. PMID: 41184587
Phytomedicine

Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES. [Abstract]

2024 Nov:134:155937. PMID: 39255723
BMC Med

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. [Abstract]

2022 Aug 24;20(1):257 PMID: 35999600
EMBO Mol Med

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. [Abstract]

2021 Apr 9;13(4):e13144. PMID: 33660397
ACS Appl Mater Interfaces

Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis. [Abstract]

2025 Jan 15;17(2):2884-2898. PMID: 39752231
Clin Sci

A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]

2021 Jul 30;135(14):1751-1765. PMID: 34282832
Sensor Actuat B-Chem

2021, 128991.
Biomed Pharmacother

Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods. [Abstract]

2025 Jun 20:189:118246. PMID: 40543162
J Transl Med

ABL1‒YAP1 axis in intestinal stem cell activated by deoxycholic acid contributes to hepatic steatosis. [Abstract]

2024 Dec 20;22(1):1119. PMID: 39707364
Biomed Pharmacother

C-kit controls blood-brain barrier permeability by regulating caveolae-mediated transcytosis after chronic cerebral hypoperfusion. [Abstract]

2024 Jan:170:115778. PMID: 38141279
Oncogene

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor. [Abstract]

2024 May 17. PMID: 38760447
Oncogene

DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6. [Abstract]

2022 Mar;41(12):1821-1834. PMID: 35140331
Cell Chem Biol

Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. [Abstract]

2018 Aug 16;25(8):996-1005.e4. PMID: 29909991

Imatinib purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4. [Abstract]

Negligible increases in caspase-3 activity or PARP-1 cleavage is observed in PC-9 GR NSCLC cells treated with DMSO, single agent PAC-1 (5 mM), or Osimertinib (Osi). In cells treated with PAC-1+Osimertinib, dramatic increases in caspase-3 activity is observed as early as 36 hr post treatment.
Clin Transl Med

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway. [Abstract]

2025 Feb;15(2):e70231. PMID: 39981588
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
J Med Chem

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. [Abstract]

2019 Jul 11;62(13):6083-6101. PMID: 31250638
J Med Chem

Discovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). [Abstract]

2019 May 23;62(10):5006-5024. PMID: 31046271
J Med Chem

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. [Abstract]

2016 Sep 22;59(18):8456-72. PMID: 27545040

Imatinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72. [Abstract]

Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.
Inflamm Regen

Imatinib inhibits pericyte-fibroblast transition and inflammation and promotes axon regeneration by blocking the PDGF-BB/PDGFRβ pathway in spinal cord injury. [Abstract]

2022 Sep 26;42(1):44. PMID: 36163271
Sci Signal

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. [Abstract]

2019 Jul 16;12(590). pii: eaav7259. PMID: 31311847
Clin Chem

Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]

2019 Dec;65(12):1522-1531. PMID: 31578215
Cell Biosci

Entry of ZSWIM4 to the nucleus is crucial for its inhibition of KIT and BMAL1 in gastrointestinal stromal tumors. [Abstract]

2024 Jun 29;14(1):87. PMID: 38951864
Cell Biosci

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib. [Abstract]

2020 Feb 12;10:16. PMID: 32082541
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
Biochem Pharmacol

AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells. [Abstract]

2023 Mar:209:115442. PMID: 36720359
Pharmaceutics

A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia. [Abstract]

2023 Sep 12;15(9):2305. PMID: 37765274
Commun Biol

TGFBI promotes liver fibrosis through remodeling the profibrotic microenvironment by a positive feedback regulatory loop. [Abstract]

2026 Feb 3;9(1):355. PMID: 41634371
Microchem J

2025 Apr.
Commun Biol

Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK. [Abstract]

2024 Jul 10;7(1):843. PMID: 38987326
Gastric Cancer

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib. [Abstract]

2023 Sep;26(5):677-690. PMID: 37222910
Drug Des Devel Ther

The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways. [Abstract]

2022 Aug 4;16:2545-2557. PMID: 35959422
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
CNS Neurosci Ther

High Shear Stress-Induced Endothelial Piezo1 Downregulation Promotes Intracranial Aneurysm Formation via the PDGF-BB/PDGFRβ Paracrine Signaling Pathway. [Abstract]

2025 Dec;31(12):e70715. PMID: 41457305
Int J Mol Sci

Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2. [Abstract]

2023 Feb 2;24(3):2849. PMID: 36769193
Biomolecules

Investigating the Effect of Tyrosine Kinase Inhibitors on the Interaction between Human Serum Albumin by Atomic Force Microscopy. [Abstract]

2022 Jun 11;12(6):819. PMID: 35740944
Int Immunopharmacol

Inhibition of the PDGFRβ/MMP-9 pathway attenuates CUMS-induced blood-brain barrier disruption, neuroinflammation, and depressive-like behaviors. [Abstract]

2026 Jul 1:180:116725. PMID: 42035550
Eur J Pharmacol

Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. [Abstract]

2021 Dec 15:913:174633. PMID: 34843676
Eur J Pharmacol

Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. [Abstract]

2021 Sep 5:906:174217. PMID: 34087223
Eur J Pharmacol

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). [Abstract]

2021 Apr 15:897:173944. PMID: 33581133
Cancer Biol Ther

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). [Abstract]

2019;20(6):877-885. PMID: 30894066
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
Ther Adv Med Oncol

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. [Abstract]

2019 May 17:11:1758835919849757. PMID: 31205508
Sci Rep

Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia. [Abstract]

2025 May 30;15(1):18978. PMID: 40447744
Sci Rep

SOCS2 inhibits the tumorigenesis of GISTs and increases the sensitivity of GISTs to imatinib by suppression of KIT activation. [Abstract]

2025 Feb 8;15(1):4779. PMID: 39922931
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Mol Cell Biochem

Adipose-derived stem cell-conditioned medium protects fibroblasts at different senescent degrees from UVB irradiation damages. [Abstract]

2020 Jan;463(1-2):67-78 PMID: 31602539
Heliyon

Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia. [Abstract]

2024 Aug 22;10(16):e36640. PMID: 39258188
Arch Pharm (Weinheim)

Synthetic flavagline derivative 1-chloroacetylrocaglaol promotes apoptosis in K562 erythroleukemia cells through miR-17-92 cluster genes. [Abstract]

2022 Oct 10;e2200367. PMID: 36216575
Viruses

Bovine Parainfluenza Virus Type 3 (BPIV3) Enters HeLa Cells via Clathrin-Mediated Endocytosis in a Cholesterol- and Dynamin-Dependent Manner. [Abstract]

2021 May 31;13(6):1035. PMID: 34072688
ChemMedChem

Synthesis of Novel d-Glucopyranuronamide-Based Nucleos(t)ide Analogs Bearing (Triazolyl)methyl Phosph(on)ate Motifs With Anticancer and Antibacterial Potential. [Abstract]

2026 Jun 26;21(12):e70328. PMID: 42315993
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Mol Carcinog

AOC3 Loss Promotes Imatinib Resistance in GIST by Stabilizing HK2 and Enhancing H3K18la-Driven Myc Transcription. [Abstract]

2026 Apr;65(4):407-421. PMID: 41570175
Mol Carcinog

Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling. [Abstract]

2024 Jul;63(7):1334-1348. PMID: 38629424
Mol Carcinog

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors. [Abstract]

2024 Jan;63(1):75-93. PMID: 37737519
Hum Cell

Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway. [Abstract]

2025 Jan 3;38(2):38. PMID: 39751699
Cancer Med

Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor. [Abstract]

2019 Sep;8(11):5352-5366. PMID: 31353847
Breast Cancer Res Treat

IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development. [Abstract]

2025 Jun;211(2):467-478. PMID: 40055251
Curr Res Toxicol

Toxicokinetics of a developmental toxicity test in zebrafish embryos and larvae: Relationship with drug exposure in humans and other mammals. [Abstract]

2024 Jul 14:7:100187. PMID: 39104612
J Tradit Complement Med

Integrating single-cell and spatial transcriptomics to elucidate the crosstalk between cancer-associated fibroblasts and cancer cells in hepatocellular carcinoma with spleen-deficiency syndrome. [Abstract]

2023 Nov 22;14(3):321-334. PMID: 38707923
J Bioenerg Biomembr

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. [Abstract]

2012 Feb;44(1):155-61. PMID: 22359102

Imatinib purchased from MedChemExpress. Usage Cited in: J Bioenerg Biomembr. 2012 Feb;44(1):155-61. [Abstract]

Differences in sensitivity of PDR-mutants to 3-BP, Imatinib methanesulfonate, Daunorubicin and Rhodamine 6 G. Minimal medium (YNB) with sucrose.
Toxicol Lett

Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. [Abstract]

2022 Jul 15:365:11-23. PMID: 35680041
Toxicol Lett

A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. [Abstract]

2022 Jun 15:363:11-26. PMID: 35597499
J Chromatogr B Analyt Technol Biomed Life Sci

Imatinib and norimatinib therapeutic monitoring using dried blood spots: Analytical and clinical validation, and performance comparison of volumetric collection devices. [Abstract]

2025 Apr 1:1255:124526. PMID: 39985852
J Chromatogr B Analyt Technol Biomed Life Sci

Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]

2024 Apr 15:1237:124100. PMID: 38547701
J Cell Biochem

Novel chemical scaffold as potential drug against Leishmania donovani: Integrated computational and experimental approaches. [Abstract]

2023 Sep;124(9):1404-1422. PMID: 37566640
Microvasc Res

The role of the PDGF-BB/PDGFR-β signaling pathway in microcirculatory disturbances and BBB destruction after experimental subarachnoid hemorrhage in mice. [Abstract]

2025 May 7:104816. PMID: 40345321
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
PLoS One

Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model. [Abstract]

2017 Jun 1;12(6):e0178619. PMID: 28570599

Imatinib purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Jun 1;12(6):e0178619. [Abstract]

The protein expression of PDGF-A, PDGF-B, PDGF-C, and PDGF-D in hearts from mice treated with vehicle, Imatinib (IMA), ISO, IMA+ISO for one week is tested by Western blot.
Biochem Biophys Res Commun

Tyrosine kinase inhibitors induce cardiotoxicity by causing Ca2+ overload through the inhibition of phosphoinositide 3-kinase activity. [Abstract]

2025 May 15:771:152027. PMID: 40403685
Anticancer Drugs

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. [Abstract]

2014 Jul;25(6):673-82. PMID: 24557015
Med Sci Monit

Platelet Derived Growth Factor Alpha (PDGFRα) Induces the Activation of Cardiac Fibroblasts by Activating c-Kit. [Abstract]

2017 Aug 6:23:3808-3816. PMID: 28780584

Imatinib purchased from MedChemExpress. Usage Cited in: Med Sci Monit. 2017 Aug 6:23:3808-3816. [Abstract]

The kinase activity of c-Kit is enhanced in an animal model of cardiac fibrosis. The lysates of heart tissues from a mice model treated with vehicle, Imatinib (IMA), ISO, or Imatinib + ISO for one week are analyzed for phosphorylation level of p-c-Kit (Tyr719) and total protein level of c-Kit. The western blotting results from one mouse in each group and the statistical analysis of the western blotting bands are shown.
In Vivo

Protective Effects of Imatinib on a DSS-induced Colitis Model Through Regulation of Apoptosis and Inflammation. [Abstract]

2024 Sep-Oct;38(5):2310-2317. PMID: 39187319
Bioanalysis

Ultra-performance LC-MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats. [Abstract]

2018 Jul;10(14):1099-1113. PMID: 30047806
Biomed Chromatogr

UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions. [Abstract]

2019 Dec;33(12):e4674. PMID: 31376170
Res Sq

2026 Jun 19.
Res Sq

2026 May 6.
Res Sq

2026 Apr 3.
bioRxiv

2026 Feb 20.
Blood Vessel Thromb Hemost

2025 Nov 17.
bioRxiv

2025 Sep 30.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

Phosphorylation-inducing chimera rewires oncogenic kinase to trigger apoptosis. [Abstract]

2025 Jun 13:2025.06.13.659082. PMID: 40661463
University of Heidelberg

2025.
Res Sq

2025 Apr 14.
bioRxiv

2025 February 26.
bioRxiv

BRAFV600 and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation. [Abstract]

2024 Dec 20:2024.12.19.629301. PMID: 39763857
Patent

US20240325538A1.
Patent

US20240238271A1.
bioRxiv

2024 June 09.
Research Square Preprint

2023 Nov 20.
Patent

US20230226111A1.
Patent

US20230158019A1.
J Pers Med

Microglia-Derived Spp1 Promotes Pathological Retinal Neovascularization via Activating Endothelial Kit/Akt/mTOR Signaling. [Abstract]

2023 Jan 11;13(1):146. PMID: 36675807
Patent

US20220288064A1.
Patent

US20220242943A1.
Patent

US20220064117A1.
Research Square Preprint

2021 May.
Patent

US20200276189A1.
Oncotarget

Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. [Abstract]

2018 Apr 24;9(31):22158-22183. PMID: 29774130

Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Apr 24;9(31):22158-22183. [Abstract]

Primary tumors are dissected at the end of experiment and subjected to immunohistochemistry. Representative images of primary tumor sections stained with anti-PCNA (proliferation), anti-cleaved caspase 3 (apoptosis), and anti-CD31 (angiogenesis).
Oncotarget

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs). [Abstract]

2017 Nov 15;8(67):111110-111118. PMID: 29340041

Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118. [Abstract]

In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.
Oncotarget

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). [Abstract]

2016 Jul 19;7(29):45562-45574. PMID: 27322145

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12.5 mg/mL (25.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0259 mL

10.1297 mL

20.2593 mL

5 mM

0.4052 mL

2.0259 mL

4.0519 mL

10 mM

0.2026 mL

1.0130 mL

2.0259 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (2.53 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 11 mg/mL (22.29 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[4]

BON-1 cells (7,500 per well) and NCI-H727 cells (5,000 per well) are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 h (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated. Experiments are done in triplicates^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[6]^[7]

Mice^[6]
The 40 tumor-bearing SCID mice are randomly divided into four groups (10 mice per group): the PS-ASODN group (5 μM, each mouse receives 0.2 mL by intratumor injection once daily); Imatinib group (0.1 mg/g body weight); liposome negative control group (0.01 mL/g); and saline group (0.01 mL/g). The mice in each group receive the relevant treatment by intra-tumor injection once daily from day 7 to day 28 after implantation. After 28 d, the mice are sacrificed, and tumor weight and longest and shortest diameters are measured by electronic scale and vernier caliper, respectively. Inhibition of tumor growth is calculated.
Rats^[7]
Adult female Wistar-Albino rats (220-240 g) are used. Twenty-one days after the first surgical procedure, the rats undergo a second laparotomy to evaluate the occurrence of endometriosis. Twenty-four rats have visually confirmed endometriotic implants and are randomized into three groups to receive Imatinib (25 mg/kg/day, p.o.), Anastrozole (0.004 mg/day, p.o.), or normal saline (0.1 mL, i.p.) for 14 days.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (293 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32. [Content Brief]

[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [Content Brief]

[3]. Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. [Content Brief]

[4]. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8 [Content Brief]

[5]. Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630. [Content Brief]

[6]. Yao JC, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40. [Content Brief]

[7]. Sun XC, et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7. [Content Brief]

[8]. Yildiz C, et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63. [Content Brief]

[9]. Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0259 mL	10.1297 mL	20.2593 mL	50.6483 mL
	5 mM	0.4052 mL	2.0259 mL	4.0519 mL	10.1297 mL
	10 mM	0.2026 mL	1.0130 mL	2.0259 mL	5.0648 mL
	15 mM	0.1351 mL	0.6753 mL	1.3506 mL	3.3766 mL
	20 mM	0.1013 mL	0.5065 mL	1.0130 mL	2.5324 mL
	25 mM	0.0810 mL	0.4052 mL	0.8104 mL	2.0259 mL

Keywords

Imatinib

127 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Imatinib

Anti-Infection Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

NMPA-Approved Drug Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

FDA Kinase Inhibitor Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Imatinib

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

Alle PDGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (127)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Imatinib Related Classifications

HY-15463 Related Classifications